Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma
|ClinicalTrials.gov Identifier: NCT00327613|
Recruitment Status : Completed
First Posted : May 18, 2006
Last Update Posted : September 26, 2008
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by apoptotic mechanism. In earlier studies, the investigators demonstrated that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential messenger ribonucleic acid (mRNA) expression and an increased fragmentation of the deoxyribonucleic acid (DNA). Such alterations point out a relationship between cellular stress and apoptotic events.
Based on the results of mRNA-expression, the investigators also expect alterations on the protein level.
This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways.
Thus the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with healthy controls. In addition, they will be also compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as a positive control in this study.
|Condition or disease|
|Pseudoexfoliation Syndrome Glaucoma|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||April 2008|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327613
|University Eye Clinic Basel|
|Basel, BS, Switzerland, 4031|
|Study Director:||Selim Orgül, MD||University Hospital, Basel, Switzerland|